^
Association details:
| Biomarker: | MLH1 methylation + MSI-H/dMMR |
|---|---|
| Cancer: | Endometrial Cancer |
| Drug: | Imfinzi (durvalumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
The impact of cause of mismatch repair deficiency and other molecular markers on clinical outcomes with the use of durvalumab in advanced endometrial cancer in the phase 2 PHAEDRA trial (ANZGOG1601).
Published date:
05/25/2023
Excerpt:
dMMR-MLH1 methylated AEC demonstrated greater heterogeneity in OTR to single agent durvalumab than the dMMR-Lynch and dMMR-somatic MMR mutation molecular subtypes. Higher TMB was seen in responders, and specifically within dMMR-MLH1 methylated responders, compared to non-responders.
DOI:
10.1200/JCO.2023.41.16_suppl.5604
